Clinical Challenges in the Management of Melanoma

Release Date: January 19, 2015 | Expiration Date: January 19, 2016
Media: Print with online posttest, evaluation, and request for credit


The panel is structured using the Medical Crossfire platform, which is based on an engaging discussion among faculty that address treatment choices, provocative questions, and challenges in the clinic. This activity is designed to aid physicians in assessing the wealth of new data, choosing treatment based upon patient and tumor characteristics, and applying those findings to their practices.

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit.  Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with melanoma. Fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers are also invited to participate.

Learning Objectives

After participating in this CME activity, learners should be better prepared to:
  • Choose treatment based on patient characteristics, such as presence of brain metastases
  • Manage toxicities of targeted and immune therapies
  • Evaluate emerging clinical data regarding new agents and evolving strategies

Medical Writer

Jennifer Klem
Disclosure: No relevant financial relationships with commercial interests to disclose.

The American Journal of Hematology/Oncology® Editorial Board Member

Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/Research Support: Genentech/Roche, Pfizer, Puma, Inc. (clinical trial support contracted to University of Southern California); Consultant: Eisai, Novartis


Adil I. Daud, MD
Clinical Professor of Medicine and Dermatology
Division of Hematology/ Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Disclosure: Grant/Research Support: Merck, Pfizer, GlaxoSmithKline, OncoSec, Novartis Pharmaceuticals, MedImmune, Genentech, Roche, and Bristol-Myers Squibb; Consultant: Genentech, Bristol-Myers Squibb, Amgen, and Celgene Corporation.

Ragini Kudchadkar, MD
Assistant Professor
Department of Hematology and Medical Oncology
Emory University Winship Cancer Institute
Atlanta, GA
Disclosure: Consultant: Bristol-Myers Squibb, and Genentech; Speaker’s Bureau: Bristol-Myers Squibb, and Genentech.

Mario Sznol, MD
Professor of Medicine (Medical Oncology)
Yale School of Medicine
Clinical Research Program Leader, Melanoma Program
Co-Director of Yale SPORE in Skin Cancer
Yale Cancer Center
New Haven, CT
Disclosure: Consultant: Bristol-Myers Squibb, Genentech, Roche, MedImmune, Amgen, Nektar, Symphogen, Merus, NeoStem, Anaeropharma, BeiGene, Kyowa-Kirin, Immune Design, Lion Biotechnologies, Seattle Genetics, and Pfizer; Stock/Shareholder: Amphivena.

Jeffrey S. Weber, MD, PhD
Senior Member and Director
Donald A. Adam Comprehensive Melanoma Research Center
Moffitt Cancer Center
Tampa, FL
Disclosure: Grant/Research Support: Bristol-Myers Squibb, GlaxoSmithKline, Merck, Genentech, Novartis Pharmaceuticals, and Macrogenetics; Consultant: Bristol-Myers Squibb, GlaxoSmithKline, Merck, Genentech, Novartis Pharmaceuticals, AstraZeneca, cCAM Biotherapeutics, Celldex Therapeutics, Altor Bioscience, and Lion Biotechnologies.

Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of PER® (Debbie Augustus, Ann C. Lichti, CCMEP and Megan O'Connell) as well as the editorial staff of The American Journal of Hematology/Oncology® (Devera Pine) have no relevant financial relationships with commercial interests to disclose.

In accordance with ACCME's Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is funded entirely by Physicians’ Education Resource®.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.


The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By